[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"persistent-covid-condition\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:persistent-covid-condition":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100575018","phase-2-study-to-evaluate-the-efficacy-and-safety-of-plitidepsin-in-adults-with-post-covid-19-condition-pcc-100575018",false,"NCT06766825","Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC)","Phase II Proof-of-concept, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC)","THALASSA","1. Male or female individuals 18 years old or older.\n2. Evidence of SARS-CoV-2 infection at least 90 days prior to study recruitment, defined by either (a) nasopharyngeal SARS-CoV-2 nucleic acid test \\[polymerase chain reaction (PCR) or transcription mediated amplification (TMA)\\], (b) validated Nasopharyngeal Lateral Flow Assay rapid antigen test (RAT), or (c) or positive serology against SARS-CoV-2 N protein regardless vaccination status.\n3. 3 or more symptoms of PCC affecting at least two organs, after 90 days from the onset of SARS-CoV2 infection and that last for at least 2 months and cannot be explained by an alternative diagnosis. Symptoms may be new onset following initial recovery from an acute COVID-19 episode or persist from the initial illness. Symptoms may also fluctuate or relapse over time.\n4. Unable to perform all usual duties\u002Factivities, defined as grades 3 or 4 in PCFS (Annex 3).\n5. Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study.\n6. Having understood the information provided and capable of providing informed consent\n\nEXCLUSION CRITERIA\n\n1. Last SARS-CoV-2 vaccine dose during the previous 30 days.\n2. Patients with active uncontrolled infections.\n3. Patients infected by SARS-CoV-2 virus in the last 90 days prior to the screening visit.\n4. Patients receiving treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers (Annex 1) throughout plitidepsin treatment period and until 24-h washout period.\n5. Pacients receiving chronic glucocorticoid therapy (high-dose corticosteroids \\[ie, 20 mg of prednisone daily or equivalent for ≥2 weeks)\n6. Any of the following cardiac conditions or risk factors:\n\n   * Cardiac infarction or cardiac surgery episode within the last six months 14\n   * History of known congenital QT prolongation;\n   * Known structural cardiomyopathy with abnormal left ventricular ejection fraction (LVEF) \\\u003C50%;\n   * Current clinical evidence of heart failure or acute cardiac ischaemia (New York Heart Association (NYHA) class III-IV).\n7. Hypersensitivity to the active ingredient or any of the excipients (mannitol, macrogolglycerol hydroxystearate, and ethanol) or contraindication to receive systemic glucocorticoids, antihistamine H1\u002FH2 receptor agents, or antiserotonine 5HT3 receptors drugs.\n8. Mast cell activation syndrome.\n9. Females who are pregnant (negative serum or urine pregnancy test required for all females of childbearing potential at screening) or breast-feeding.\n10. Females of childbearing potential (females who are not surgically sterile or postmenopausal defined as amenorrhea for \\>12 months) who are not using highly effective contraceptive methods, while on study treatment and for 6 months after last dose of plitidepsin. Fertile males with partners of childbearing potential must use condom during treatment and for 6 months after last dose of plitidepsin. Refer to Annex 2 for contraception requirements.\n11. Unable to consent and\u002For comply with study requirements, in the opinion of the investigator.\n12. Currently participating or participated in a clinical trial within the prior","ALL","18 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The study aims to prove that plitidepsin could be an efficacious, safe, and well-tolerated therapy for PCC. To this end, we will perform a randomized, double-blind study comparing the clinical and laboratory benefits of plitidepsin vs. placebo in 90 subjects with moderate to severe functional disability. The study consists of an intervention period and a follow-up period, with a total of 135 +\u002F-3 days approximately between both periods.\n\nDuring the intervention period, four treatment cycles will be administered, scheduled every 15 days (every 2 weeks), with intravenous (IV) infusion over three consecutive days. After completing the intervention period, a 90-day (+\u002F-5) follow-up period will be conducted.\n\nSubjects in arm A will receive the plitidepsin 1.5 mg\u002Fday 1h-IV during the four treatment periods on Days 1 to 3, Days 15 to 17, Days 29 to 31 and Days 43 to 45. Subjects in arm B will receive 1h-IV placebo 1 vial \u002Fday during the first two treatment periods and will receive the plitidepsin 1.5 mg\u002Fday 1h-IV during the last two treatment periods. Subjects in arm C will receive 1h-IV placebo 1 vial\u002Fday during the four treatment periods.",[27,28,29,30,31],"Post COVID-19 Condition","Long COVID Syndrome","Persistent COVID-19","Persistent COVID Condition","Long COVID",[33,34,35,36],"SARS-CoV-2","COVID-19","Long COVID19","Plitidepsin","RECRUITING","2026-04-02",{"date":40,"type":41},"2026-04-03","ACTUAL",{"date":43,"type":41},"2025-02-07",{"date":45,"type":21},"2026-09-01",{"name":47,"class":48},"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":59,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":49},"100615659","predictors-of-long-term-evolution-in-long-covid-4-year-follow-up-bioicoper-follow-up-study-100615659","NCT07295483","Predictors of Long-Term Evolution in Long COVID; 4-Year Follow-Up. (BioICOPER Follow-up Study)","To Analyze the Determining Factors in the Evolution of Subjects Diagnosed With Long COVID at Four Years of Follow-up. BioICOPER Follow-up Study.","Inclusion Criteria:\n\n* Adults ≥18 years old.\n* Confirmed previous SARS-CoV-2 infection.\n* Diagnosis of long COVID according to WHO criteria.\n* Participation in the baseline BioICOPER study.\n* Signed informed consent for re-evaluation.\n\nExclusion Criteria:\n\n* Acute illness preventing participation.\n* Cognitive or physical impairment limiting data collection.\n* Withdrawal of informed consent.\n* Age \\\u003C 18 years old",{"count":58,"type":21},400,"4 Years","OBSERVATIONAL","Long COVID (persistent COVID) represents a major global health challenge due to its high prevalence (approximately 7%), significant impact on quality of life, and socioeconomic burden. Despite extensive research, diagnostic tools to objectively identify or predict long COVID evolution are still lacking.\n\nThe BioICOPER Follow-up Study aims to analyze the influence of biomarker evolution on clinical symptomatology (particularly chronic fatigue) and vascular health after four years of follow-up among 400 participants previously included in the original BioICOPER cohort.\n\nAdvanced proteomic analysis, vascular function assessment, and machine-learning-based predictive modeling will be used to identify biomarkers associated with disease progression, stratified by sex. This project will contribute to personalized clinical management of long COVID and improved diagnostic and therapeutic strategies in primary care.",[30],[64,65,66,67,68,69,70],"Post-acute COVID syndrome","Vascular aging","Proteomics","Biomarkers","Machine learning","Persistent COVID","Artificial Intelligence","2026-03-10",{"date":73,"type":41},"2026-03-12",{"date":75,"type":41},"2026-02-09",{"date":77,"type":21},"2029-06",{"name":79,"class":48},"Instituto de Investigación Biomédica de Salamanca"]